Export 2717 results:
Author Title [ Type(Desc)] Year
Journal Article
W. T. Wong, Kam, W., Cunningham, D., Harrington, M., Hammel, K., Meyerle, C. B., Cukras, C., Chew, E. Y., Sadda, S. V. R., and Ferris, F. L., “Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial.”, Invest Ophthalmol Vis Sci, vol. 51, no. 12, pp. 6131-9, 2010.
W. Wong, Kam, W., Cunningham, D., Harrington, M., Hammel, K., Meyerle, C., Cukras, C., Chew, E., Sadda, S., and Ferris, F., “Treatment of Geographic Atrophy by the Topical Administration of OT-551: Results of a Phase II Clinical Trial”, Invest Ophthlmol Vis Sci, vol. 51, pp. 613-619, 2010.
G. Gensler, Clemons, T. E., Domalpally, A., Danis, R. P., Blodi, B., Wells, J., Rauser, M., Hoskins, J., G Hubbard, B., Elman, M. J., Fish, G. E., Brucker, A., Margherio, A., and Chew, E. Y., “Treatment of Geographic Atrophy with Intravitreal Sirolimus: The Age-Related Eye Disease Study 2 Ancillary Study.”, Ophthalmol Retina, vol. 2, no. 5, pp. 441-450, 2018.
W. T. Wong, Dresner, S., Forooghian, F., Glaser, T., Doss, L., Zhou, M., Cunningham, D., Shimel, K., Harrington, M., Hammel, K., Cukras, C. A., Ferris, F. L., and Chew, E. Y., “Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial.”, Invest Ophthalmol Vis Sci, vol. 54, no. 4, pp. 2941-50, 2013.
W. T. Wong, Dresner, S., Forooghian, F., Glaser, T., Doss, L., Zhou, M., Cunningham, D., Shimel, K., Harrington, M., Hammel, K., Cukras, C., Ferris, F. L., and Chew, E. Y., “Treatment of Geographic Atrophy with Subconjunctival Sirolimus: Results of a Phase I/II Clinical Trial”, Invest Ophthalmol Vis Sci, vol. 54, pp. 2941-2950, 2013.
B. D. Cheson, Sorensen, J. M., Vena, D. A., Montello, M. J., Barrett, J. A., Damasio, E., Tallman, M., Annino, L., Connors, J., Coiffier, B., and Lauria, F., “Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients.”, J Clin Oncol, vol. 16, no. 9, pp. 3007-15, 1998.
J. Smith, Thompson, D., Whitcup, S., Suhler, E., Clarke, G., Robinson, M., and Baron, K., “The treatment of JRA-associated uveitis with Etanercept”, 2002.
R. B. Nussenblatt, Fortin, E., Schiffman, R., Rizzo, L., Smith, J., Van Veldhuisen, P., Sran, P., Yaffe, A., Goldman, C. K., Waldmann, T. A., and Whitcup, S. M., “Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.”, Proc Natl Acad Sci U S A, vol. 96, no. 13, pp. 7462-6, 1999.
R. B. Nussenblatt, Fortin, E., Schiffman, R., Rizzo, L., Smith, J., Van Veldhuisen, P., Sran, P., Yaffe, A., Goldman, C. K., Waldmann, T. A., and Whitcup, S. M., “Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial”, Proceedings of the National Academy of Science USA, vol. 96, pp. 7462-66, 1999.
E. Atallah, Bylow, K., Troy, J., and Saber, W., “Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).”, Curr Hematol Malig Rep, vol. 9, no. 1, pp. 57-65, 2014.
E. Atallah, Bylow, K., Troy, J., and W, S., “Treatment of Older Patients with High-Risk Myelodysplastic Syndromes (MDS): the Emerging Role of Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT)”, Curr Hematol Malig Rep, vol. 9, pp. 57-65, 2014.
J. M. Sorensen, Vena, D. A., Fallavollita, A., Chun, H. G., and Cheson, B. D., “Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report.”, J Clin Oncol, vol. 15, no. 2, pp. 458-65, 1997.
V. DA, “Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute; 5-year follow-up report,”, J Clin Oncol, vol. 15, 1997.
K. A. Holtz, Szefer, E., Noonan, V. K., Kwon, B. K., and Mills, P. B., “Treatment patterns of in-patient spasticity medication use after traumatic spinal cord injury: a prospective cohort study.”, Spinal Cord, vol. 56, no. 12, pp. 1176-1183, 2018.
O. Gasser, Bihl, F., Sanghavi, S., Rinaldo, C., Rowe, D., Hess, C., Stablein, D., Roland, M., Stock, P., and Brander, C., “Treatment-Dependent Loss of Polyfunctional Cd8+ T-Cell Responses in HIV-Infected Kidney Transplant Recipients Is Associated with Herpesvirus Reactivation”, Am J Transplant, vol. 9, pp. 794-803, 2009.
O. Gasser, Bihl, F., Sanghavi, S., Rinaldo, C., Rowe, D., Hess, C., Stablein, D., Roland, M., Stock, P., and Brander, C., “Treatment-dependent loss of polyfunctional CD8+ T-cell responses in HIV-infected kidney transplant recipients is associated with herpesvirus reactivation.”, Am J Transplant, vol. 9, no. 4, pp. 794-803, 2009.
A. Veitz-Keenan, Barna, J. Ann, Strober, B., Matthews, A. G., Collie, D., Vena, D., Curro, F. A., and Thompson, V. P., “Treatments for hypersensitive noncarious cervical lesions: a Practitioners Engaged in Applied Research and Learning (PEARL) Network randomized clinical effectiveness study.”, J Am Dent Assoc, vol. 144, no. 5, pp. 495-506, 2013.
A. Veitz-Keenan, Barna, J. A., Strober, B., Matthews, A. G., Collie, D., Vena, D., Curro, F. A., and Thompson, V. P., “Treatments for Hypersensitive Noncarious Cervical Lesions: A Practitioners Engaged in Applied Research and Learning (PEARL) Network Randomized Clinical Effectiveness Study”, J Am Dent Assoc, vol. 144, pp. 495-506, 2013.
S. DM, “Trend in immunosuppressive therapy: A report of the North American Pediatric Cooperative Study (NAPRTCS)”, 1998.
M. R. Benfield, Stablein, D., and Tejani, A., “Trends in immunosuppressive therapy: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).”, Pediatr Transplant, vol. 3, no. 1, pp. 27-32, 1999.
M. Benfield, Stablein, D., and Tejani, A., “Trends in immunosuppressive therapy: A report of the North American Pediatric Cooperative Study (NAPRTCS)”, Pediatr Transplantation, vol. 3, pp. 27-32, 1999.
R. J. Levine, Esterlitz, J. R., Raymond, E. G., DerSimonian, R., Hauth, J. C., Ben Curet, L., Sibai, B. M., Catalano, P. M., Morris, C. D., Clemens, J. D., Ewell, M. G., Friedman, S. A., Goldenberg, R. L., Jacobson, S. L., Joffe, G. M., Klebanoff, M. A., Petrulis, A. S., and Rigau-Perez, J. G., “Trial of Calcium for Preeclampsia Prevention (CPEP): rationale, design, and methods.”, Control Clin Trials, vol. 17, no. 5, pp. 442-69, 1996.
E. M. G. Esterli JR, “Trial of calcium for preeclampsia prevention (CPEP): rationale, design and methods,”, Control Clin Trials, vol. 17, pp. 442-69, 1996.
R. J. Levine, Hauth, J. C., Curet, L. B., Sibai, B. M., Catalano, P. M., Morris, C. D., DerSimonian, R., Esterlitz, J. R., Raymond, E. G., Bild, D. E., Clemens, J. D., and Cutler, J. A., “Trial of calcium to prevent preeclampsia.”, N Engl J Med, vol. 337, no. 2, pp. 69-76, 1997.
S. Shenoy, Eapen, M., Panepinto, J. A., Logan, B. R., Wu, J., Abraham, A., Brochstein, J., Chaudhury, S., Godder, K., Haight, A. E., Kasow, K. A., Leung, K., Andreansky, M., Bhatia, M., Dalal, J., Haines, H., Jaroscak, J., Lazarus, H. M., Levine, J. E., Krishnamurti, L., Margolis, D., Megason, G. C., Yu, L. C., Pulsipher, M. A., Gersten, I., DiFronzo, N., Horowitz, M. M., Walters, M. C., and Kamani, N., “A trial of unrelated donor marrow transplantation for children with severe sickle cell disease.”, Blood, vol. 128, no. 21, pp. 2561-2567, 2016.